- Peptide (C)NGSKDGLDSNPMKD, corresponding to amino acid residues 11-24 of human CB2 receptor (Accession P34972). Extracellular, N-terminus.
- Western blot analysis of human HL-60 acute promyelocytic leukemia cell line lysate (lanes 1 and 2) and human MCF-7 breast adenocarcinoma cell line lysate (lanes 3 and 4):1,3. Anti-Human Cannabinoid Receptor 2 (extracellular) Antibody (#ACR-003), (1:200).
2,4. Anti-Human Cannabinoid Receptor 2 (extracellular) Antibody, preincubated with Human Cannabinoid Receptor 2 (extracellular) Blocking Peptide (#BLP-CR003).
- Expression of CB2 receptor in human LNCaPImmunocytochemical staining of living human prostate carcinoma cells (LNCaP). A. Extracellular staining of cells with Anti-Human Cannabinoid Receptor 2 (extracellular) Antibody (#ACR-003), (1:50), followed by goat-anti-rabbit-AlexaFluor-488 secondary antibody. B. Nuclear staining of LNCaP cells with Hoechst 33342. C. Live intact LNCaP cells.
- Cell surface detection of CB2 receptor by indirect flow cytometry in live intact human THP-1 monocytic leukemia cells:___ Cells.
___ Cells + goat-anti-rabbit-FITC.
___ Cells + Anti-Human Cannabinoid Receptor 2 (extracellular) Antibody (#ACR-003), (2.5μg) + goat-anti-rabbit-FITC.
- Brooks, J.W. and Fraquhar-Smith, M.A. (2003) Br. J. Anaesth. 3, 175.
- Howlett, A.C. (2002) Prostaglandins Other Lipid Mediat. 68, 619.
- Guo, J. and Ikeda, S.R. (2004) Mol. Pharmacol. 65, 665.
- Wotherspoon, G. et al. (2005) Neuroscience 135, 235.
- Gong, J.P. et al. (2006) Brain Res. 1071, 10.
- Fernandez-Ruiz, J. et al. (2007) Trends Pharmacol. Sci. 28, 39.
- Sarfaraz, S. et al. (2005) Cancer Res. 65, 1635.
- Sanchez, C. et al. (2001) Cancer Res. 61, 5784.
- Alberich Jorda, M. et al. (2004) Blood 104, 526.
Cannabinoids have been used as pain relievers in Eastern medicine for many years.1 To date, two specific cannabinoid receptors have been identified: cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).2 The cannabinoid receptors can be distinguished by their amino acid sequence, signaling mechanisms and tissue distribution.2 Both receptors belong to the G-protein coupled receptor superfamily and are coupled to Gi/0 G protein.2,3
The CB2 is highly expressed in cells of the immune system such as macrophages, lymphocytes natural killer cells and mast cells but has also been shown to be expressed, by both, in situ-hybridization and in immunohistochemistry, in spleen, thymus, and pancreas.1,2,4 CB2 expression in brain is still much less characterized than that of CB1. Recently, it was demonstrated that CB2 is expressed in the brain and might have a role in controlling fundamental processes such as proliferation and survival of neural cells.5,6
Overexpression of CB2 was reported in several cancers such as prostate, glioma and acute myeloid leukemias.7-9 In human astrocytoma a direct relation between CB2 expression and tumor malignancy was demonstrated.8 Activation of CB2R in vivo by its agonist JWH-133, completely blocked cell growth.8 In C6 glioma, it was shown that activation of the CB2 by JWH-133 resulted in internalization of only the CB2 and not CB1 leading to apoptosis of the cells. This may well be a new approach for the treatment of glioma.
Species reactivity key:
Alomone Labs is pleased to offer a highly specific antibody directed against an extracellular epitope of the human CB2 receptor. Anti-Human Cannabinoid Receptor 2 (extracellular) Antibody (#ACR-003) can be used in western blot, immunohistochemistry and live cell imaging applications. It has been designed to recognize CB2 from human samples. The antibody is not recommended for use on rat and mouse samples.
- Anti-Cannabinoid Receptor 2 Antibody (#ACR-002).
This antibody recognizes a different epitope and thus can also be used as a control for detecting CB2R.